Outgoing West Virginia Gov
Superior Weight Loss With Once-Weekly Semaglutide Versus Other Glucagon-Like Peptide-1 Receptor Agonists is Independent of Gastrointestinal Adverse Events
The analysis of pharmacovigilance for a drug, utilizing postmarketing safety databases like the FAERS, plays a crucial role in the ongoing management of risks by detecting safety signals that may not have been identified during the drugs clinical development phase [Reference Anand, Ensor, Trachtenberg and Bernicker10, Reference Jedlowski, Jedlowski and Fazel14, Reference Egeberg and Thyssen32Reference Yu, Krantz, Phillips and Stone35]
While the clinical evaluation of GLP-1MK-801 for weight loss awaits, efforts to broaden the scope of developing peptide-mediated targeting of ion channels are encouraged and should not be restricted to metabolic diseases
We can correct it
The need for efficient remedies like GLP-1 therapies is only increasing because of the rise in sedentary lifestyles and poor diets
